AOD 9604 5 mg: distinguish labeled vial mass from aliquots and human dosing, with formulation-specific preparation, stability, and oral clinical trial context.
AOD 9604 5 mg refers to a sample labeled as containing 5 milligrams of AOD-9604. Vial mass does not establish purity-adjusted content, solubility, a human dose, or how long an experiment will last. AOD-9604 has no FDA-approved human drug product.
Anyone considering it outside a lab should speak with a licensed healthcare professional first. Human safety data remain limited, and no online protocol replaces medical supervision.
What AOD 9604 Is and Why the 5 mg Vial Matters
AOD-9604 contains hGH residues 177-191 with an additional N-terminal tyrosine, making a modified 16-amino-acid peptide. The common name HGH fragment 176-191 should not be read as an unchanged native sequence. A metabolic research rationale is not a guarantee of fat loss without glucose or growth-related effects.
Quick reference for the compound:
- Identity: AOD-9604 is a modified 16-amino-acid peptide, not the unchanged native 177-191 fragment.
- Free-base molecular weight: approximately 1815.09 g/mol; the acetate form has a different formula weight.
- Free-base CAS listed in the 2024 FDA evaluation: 221231-10-3; check the actual form and sequence because supplier identifiers can be inconsistent.
- A powder appearance or vial size does not establish identity, actual peptide content, or sterility.
A 5 mg label indicates total nominal mass. Cost and experimental duration depend on the product, independently specified aliquots, losses, formulation, and stability; vial size alone does not establish a multi-week protocol.
AOD 9604 Reconstitution: Mixing the 5 mg Vial
Reconstitution means dissolving a sample in a compatible solvent. An aod 9604 reconstitution guide must identify the actual form and formulation; bacteriostatic water is not automatically appropriate for every AOD-9604 sample.
For a laboratory preparation, establish the following before treating a calculation as usable:
- Identify the form, batch, actual content, and intended assay.
- Use documented solvent compatibility and preparation conditions.
- Record final solution volume, assuming complete dissolution for concentration arithmetic.
- Do not use a cloudy, precipitated, or gelled sample or assume clarity proves sterility.
- Use storage and stability information supported for that preparation.
As hypothetical arithmetic, 5 mg in a final volume of 1 mL gives 5 mg/mL; 0.10 mL, or 10 U-100 units, contains 500 mcg. In a final volume of 2 mL it contains 250 mcg. These are specified laboratory aliquots, not human doses or validated preparation recipes.
AOD 9604 Dosage Used in Research
No validated human subcutaneous aod 9604 dosage follows from the reviewed record. The human program included substantial oral research; it was not limited to short, small trials or validated daily microgram injections.
The following table counts hypothetical laboratory aliquots from a nominal 5 mg sample, assuming no loss. It does not define days of treatment or a stable shelf life:
| Specified aliquot | Arithmetic yield from 5 mg | Interpretation |
|---|---|---|
| 300 mcg | 16 complete aliquots, with 200 mcg remaining | No recommended human amount or duration |
| 500 mcg | 10 aliquots | No recommended human amount or duration |
| 1 mg | 5 aliquots | No recommended human amount or duration |
Online dosing charts are anecdotal, not clinical. A number that worked for one person in a forum post has no established safety record behind it.
AOD 9604 Benefits and Side Effects Reported So Far
For aod 9604 benefits and side effects, clinical history matters. The larger oral obesity trial summarized in FDA's 2024 AOD-9604 evaluation enrolled 536 people and randomized 502 to placebo or 0.25, 0.5, or 1 mg daily for 24 weeks. It did not show a significant advantage on the primary weight-loss endpoint at 12 weeks. Oral trial arms are not human injection recommendations.
Keep mechanistic observations and clinical interpretation separate:
- Metabolic effects in animal or cell models are research hypotheses for humans.
- Intended differences from full growth hormone do not guarantee glucose or IGF-1 safety.
- Bodybuilding and muscle-retention benefits are not established by the reviewed clinical evidence.
- Earlier signals did not establish a significant benefit in the larger oral obesity trial.
The 2024 review assessed oral and intravenous human safety information, not a generally mild subcutaneous profile. Some serious oral events lacked enough information to establish causality. These findings cannot establish long-term injection safety.
How AOD 9604 Compares With Tesamorelin, MOTS-c, and Retatrutide
Researchers often compare aod 9604 vs tesamorelin because both are studied for fat reduction, but the two work in different ways. Tesamorelin is a growth hormone-releasing hormone analog that is FDA-approved for a specific condition, while AOD-9604 is not approved for any human use.
For aod 9604 vs retatrutide, compare the actual receptor mechanism, route, populations, endpoints, and outcomes. A newer program or a different vial size does not establish AOD-9604 effectiveness or dose equivalence.
| Compound | Relevant distinction | Interpretation |
|---|---|---|
| AOD-9604 | Modified growth-hormone fragment with a substantial oral clinical program | No FDA-approved human product; larger oral trial missed its primary endpoint |
| Tesamorelin | Prescription GHRH analog for a specific HIV-related indication | Its label does not validate AOD-9604 treatment |
| MOTS-c | Different metabolic peptide | Mechanism does not establish equivalent effects |
| Retatrutide | Different receptor-agonist development program | Its own trials cannot establish AOD-9604 outcomes |
| Tirzepatide | Approved prescription products for defined indications | Approval does not validate an AOD-9604 stack |
The clinical record should be compared by study design and outcome rather than age or marketing popularity. AOD-9604 had a sizeable oral obesity trial, but it did not establish the intended weight-loss benefit or a validated human subcutaneous regimen.
Storage, Purity, and What a 5 mg Vial Costs
The 2024 evaluation explains that formulation, pH, concentration, temperature, impurities, and excipients can affect aggregation and degradation. It does not validate one diluent, acid recipe, or shelf life for every AOD-9604 product. A general cool-place, freezer, refrigerator, or few-weeks rule is not a validated shelf life for every powder and solution.
Things to check before buying:
- Purity: a chromatographic percentage does not by itself establish milligrams of peptide, sterility, or endotoxin control.
- Certificate: match batch, form, date, laboratory, method, and the actual tests performed.
- Price: compare current quotations and measured quality attributes rather than an unsupported universal market range.
- Labeling: a research-use statement does not guarantee quality or authorize human treatment.
Price alone cannot establish correct identity, purity, or fraud. A low or high quote needs the same batch-specific evidence.
Legal Status and Safety Reminders
AOD-9604 has no FDA-approved human drug product. A research-use label does not by itself establish lawful marketing or resolve applicable treatment and compounding requirements.
- Human-treatment marketing is subject to applicable drug and product rules.
- Analytical purity is not a sterility or suitability guarantee.
- The reviewed evidence does not establish safety in pregnancy, breastfeeding, or relevant medical conditions.
- Clinical discussion can clarify evidence gaps; it cannot make a research sample an approved product.
Anyone using AOD-9604 for personal fat loss is doing so outside approved medical use and without long-term safety data.
The Bottom Line on AOD 9604 5 mg
A 5 mg vial is a quantity label, not proof of easy reconstitution or a clinical course. Use formulation-specific evidence and transparent aliquot arithmetic; the human oral record does not establish a validated weight-loss injection regimen.
For general wellness and weight goals, evidence-based options reviewed with a physician remain the safer path.
Frequently Asked Questions
What is AOD 9604 5 mg used for?
It denotes a sample labeled as containing 5 mg of AOD-9604 for research. Vial mass does not select a human dose or guarantee actual peptide content. AOD-9604 has no FDA-approved human product, and the larger oral obesity trial missed its primary weight-loss endpoint.
How much bacteriostatic water do I add to an AOD 9604 5 mg vial?
No universal solvent or volume is established. As arithmetic only, a fully dissolved 5 mg sample in a final volume of 1 mL gives 5000 mcg/mL, while 2 mL gives 2500 mcg/mL. A 0.10 mL aliquot therefore contains 500 or 250 mcg respectively; compatibility and stability must be established separately.
Is AOD 9604 FDA-approved or legal to use in the US?
No FDA-approved AOD-9604 human drug product exists. A research-use label does not authorize treatment or guarantee lawful marketing, quality, or safety. Purchasing, possession, and compounding depend on the applicable product and practice requirements.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.